IL-15 enhanced antibody-dependent cellular cytotoxicity mediated by NK cells and macrophages

Previously we demonstrated that IL-15 by continuous infusion at 2 μg/kg/d for 10 days induced a 38-fold increase in circulating natural killer (NK) cells and a 358-fold increase in CD56 bright NK cells. In the present study we demonstrated that IL-15 enhanced antibody-dependent cellular cytotoxicity...

Full description

Bibliographic Details
Authors: Zhang, Meili, Wen, Bernard, Antón Hurtado, Olga María, Yao, Zhengsheng, Dubois, Sigrid, Ju, Wei, Sato, Noriko, DiLillo, David, Bamford, Richard, Ravetch, Jeffrey, Waldmann, Thomas
Format: article
Publication Date:2018
Country:España
Institution:Universidad Complutense de Madrid (UCM)
Repository:Docta Complutense
Language:English
OAI Identifier:oai:docta.ucm.es:20.500.14352/97029
Online Access:https://hdl.handle.net/20.500.14352/97029
Access Level:Open access
Keyword:576
Biología celular (Biología)
2407 Biología Celular
Description
Summary:Previously we demonstrated that IL-15 by continuous infusion at 2 μg/kg/d for 10 days induced a 38-fold increase in circulating natural killer (NK) cells and a 358-fold increase in CD56 bright NK cells. In the present study we demonstrated that IL-15 enhanced antibody-dependent cellular cytotoxicity (ADCC) of tumor-directed monoclonal antibodies in two systems. Both NK cells and macrophages were required for optimal therapeutic responses. These studies support clinical trials of IL-15 combined with tumor-directed monoclonal antibodies. In translation of this study, a phase I trial of IL-15 combined with alemtuzumab has been opened for patients with adult T cell leukemia (ATL) NCT02689453.

Similar Items